VivoSeq
Oncology

Non Muscle Invasive Bladder Cancer

9

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Non Muscle Invasive Bladder Cancer is an early-stage landscape with 9 programs across 5 companies. The most active players are Protara Therapeutics, AstraZeneca, Ferring. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Protara Therapeutics

1 program

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 3Ferring logo

Ferring

1 program

Phase 3C

CG Oncology, Inc.

2 programs

Phase 3Merck & Co. logo

Merck & Co.

3 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

6programs
Small molecule233%
Gene therapy233%
Monoclonal antibody117%
Antibody–drug conjugate117%

Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

7

clinical trials

Active, not recruiting4 · 57%
Recruiting3 · 43%

Clinical Trials

Trial Activity

7 trials

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT06637423·32 enrolled
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Recruiting·Ferring logoFerring·Phase 3·NCT06510374·454 enrolled
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
Recruiting·PProtara Therapeutics·Phase 2·NCT05951179·131 enrolled
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)
Active, not recruiting·CCG Oncology, Inc.·Phase 3·NCT04452591·190 enrolled
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT03528694·1,018 enrolled
A Phase 1b, Single Arm Study of CG0070 After Transurethral Resection in Patients With Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06253845·20 enrolled
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Active, not recruiting·CCG Oncology, Inc.·Phase 3·NCT06111235·367 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)